gdc
Lung CancerFDA Approvals, News & Updates

FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations

In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the second MET inhibitor that has been approved by the FDA.
February 2021 Vol 7 No 1

In February 2021, the FDA approved Tepmetko (tepotinib; from EMD Serono), a new oral targeted therapy, for the treatment of adults diagnosed with metastatic non–small-cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. This new tablet is appropriate for patients who have not received any previous therapy as well as for patients who have received previous therapy.

Tepmetko is the second MET inhibitor that has been approved by the FDA. It should be selected for treatment after the patient has had a genetic testing showing the presence of METex14 skipping alterations.

METex14 skipping occurs in approximately 3% to 4% of NSCLC cases, and patients with this aggressive lung cancer are often elderly and face a poor clinical prognosis,” said Paul K. Paik, MD, lead investigator and Clinical Director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. “There is a pressing need for targeted treatments that have the potential to generate durable anti-tumor activity and improve the lives of patients with this challenging disease.”

“The availability of a new precision medicine for NSCLC with METex14 skipping alterations advances patient access to targeted treatment and underscores the importance of routine comprehensive biomarker testing for patients with this challenging cancer,” said Andrea Ferris, LUNGevity President and CEO.

The FDA approved Tepmetko based on the results from a clinical trial that included 152 patients with advanced or metastatic NSCLC and METex14 skipping alterations. In all, 69 patients had not received previous therapy and 83 patients had received previous therapy. In the study, all patients received skipping treatment with Tepmetko tablets once daily, until their disease progressed or until they had unacceptable side effects. The main efficacy outcome measures were overall response rate and duration of response.

Among the 69 who had not received previous treatment for lung cancer, 43% of the patients had a response to treatment with Tepmetko, and the average duration of response was 10.8 months. Similarly, among the 83 patients who received previous treatment, 43% of the patients had a response to treatment with Tepmetko, and the average duration of response was 11.1 months.

The most common side effects with Tepmetko were swelling, fatigue, nausea, diarrhea, musculoskeletal pain, and difficulty breathing.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma. Ukoniq is used for MZL after 1 or more anti-CD20 therapies, and for follicular lymphoma after 3 or more lines of systemic therapy. Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta First Gene Therapy Approved for Follicular Lymphoma
In March 2021, the FDA approved a new indication for Yescarta (axicabtagene ciloleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of patients with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
In March 2021, the FDA approved Abecma (idecabtagene vicleucel; from Bristol Myers Squibb/Bluebird Bio), a BCMA-directed, genetically modified CAR T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or returned, after 4 or more lines of therapy. Abecma is the first gene therapy approved by the FDA for the treatment of multiple myeloma.
Last modified: March 12, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country